MSHLTucatinib Tablet 50 mg, 150 mg
For the treatment of locally advanced unresectable or metastatic HER2-positive breast cancer in combination with trastuzumab and capecitabine in patients who have received one or more prior anti-HER2-based regimens in the metastatic setting.